Why the study?
Does statin therapy increase the risk of developing psychologic disorders in a military population?
Does statin therapy increase the risk of developing psychologic disorders in a military population?
Statin therapy is not associated with an increased risk of developing psychologic disorders such as schizophrenia, major depression, or bipolar disorder in a propensity-matched military cohort.
Answers are grounded in this paper and cite their sources.
No psychologic risk signal seen with statins; observational data leaves open need for randomized confirmation.
Study Objective To evaluate the association between statin therapy and the risk of psychologic disorders including schizophrenia, psychosis, major depression, and bipolar disorder in a military population. Design Retrospective, observational, population‐based, propensity score‐matched, cohort study. Setting Database of a patient population enrolled in the San Antonio Military Multi‐Market Area as Tricare Prime or Plus. Patients Medical records were reviewed from 46,249 patients aged 30–85 years who were continuously enrolled in the San Antonio Military Multi‐Market Area as Tricare Prime or Plus from October 1, 2003–March 1, 2010. Data were obtained from the Military Health System Management Analysis and Reporting Tool (M2). Based on drug fills during fiscal year 2005, patients were stratified as statin users (13,626 patients received at least 90‐days supply of statin) or nonusers (32,623 patients never received a statin during the study period). A propensity score‐matched cohort of 6972 statin users and 6972 nonusers from this population was created. Measurements and Main Results The occurrence of psychologic disorders between October 1, 2005, and March 1, 2010, was determined using prespecified groups of ICD‐9‐CM, Psych1: schizophrenia, schizoaffective disorders, and other psychosis; Psych2: major depression and bipolar disorder; Psych3: all psychologic disorders as identified by the Agency for Health Research and Quality‐Clinical Classifications (except for categories of childhood or developmental psychiatric disorders). Between matched pairs of statin users and nonusers, the odds ratios and 95% confidence intervals were as follows: Psych1 (0.9, 0.75–1.05), Psych2 (1.02, 0.94–1.11), and Psych3 (1.02, 0.96–1.1), respectively. Conclusion The risk of developing psychologic disorders was similar in this cohort of propensity score‐matched statin users and nonusers.
No takes yet. Share an insight, caveat, or question.
Mansi et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: